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ABSTRACT
Since 2011, GAVI, The Vaccine Alliance, has funded eligible countries to introduce rubella-containing
vaccination (RCV) into their national schedule. Two key indicators used to monitor the impact – the
future deaths and DALYs (Disability Adjusted Life Years) averted through vaccination conducted in
specific periods – are poorly understood for rubella and Congenital Rubella Syndrome (CRS). We
calculate these indicators using an age-structured dynamic transmission model for rubella, with histor-
ical vaccination coverage projections during 2001–30 in 92 low and middle-income countries considered
most likely to require global support to achieve the Global Vaccine Action Plan’s objectives. 131,000 CRS
deaths and 12.5 million DALYs may be prevented with immunization campaigns at best-estimate
coverage during 2001–30, relative to those without additional support. The impact depended on the
time period considered and the method for attributing deaths averted to vaccination in specific periods.
The analyses support ongoing activities to reduce CRS-related morbidity and mortality.
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Introduction
Approximately 105,000 children are born annually with
Congenital Rubella Syndrome (CRS),1 a preventable cause of
infant mortality, associated with lifelong disability, including
cardiac defects, deafness, cataracts and mental retardation.2
Rubella vaccination is the primary method used to prevent
CRS.2 The preferred strategy is to vaccinate a wide age-range
(9 months to at least 15 years) in a campaign and then
introduce routine infant rubella vaccination.2 Since 2012,
GAVI, the Vaccine Alliance has funded eligible countries to
conduct Measles-Rubella (MR) vaccination with this
approach,3,4 which reduces rubella virus transmission in the
population, and ensures that vaccinated girls are immune by
child-bearing age.2 GAVI presently measures its progress in
delivering strategic goals using the number of future deaths
and Disability Adjusted Life Years (DALYs) averted through
vaccination conducted in a given period with externally-sup-
ported vaccine.5,6
Although such indicators are helpful for contrasting the
impact of vaccines for different diseases and vaccination in
different periods, they are not straightforward to calculate and
interpret for CRS. This follows from the facts that CRS-related
disability and deaths are prevented many years after vaccina-
tion usually occurs, given that CRS may follow in a child if
his/her non-immunised mother was infected with rubella
when pregnant.2 When calculating the indicators, two factors
then need to be accounted for when attributing disability and
death averted due to vaccines administered during a given
period. The first is whether a woman was vaccinated as a
child. The second is the population-level immunity. This is
influenced by the vaccination coverage in the population and
it determines the amount of ongoing rubella transmission and
therefore the risk of non-immunized mothers becoming
infected when pregnant.2 Consequently, both the vaccination
coverage among pregnant women during their childhood and
the population-level coverage thereafter influence the disabil-
ity and death averted due to vaccines administered in a
specific period.
To date, no studies have either estimated the reduction in
the burden of CRS that is attributable to vaccines adminis-
tered in specific periods, accounting for these complications,
or presented methods for calculating those reductions.
Instead. modelling studies have considered the minimum
level of coverage required to prevent increases in the burden
of CRS7 and its sensitivity to the population birth rate and
other factors,8 the impact of vaccination in the private sector
on the burden of CRS,9 and the relative merits of introducing
routine immunization compared to vaccinating teenage girls.
This paper uses mathematical modelling to calculate the num-
ber of future deaths and DALYs averted until 2081 because of
vaccination conducted in different periods during 2001–30,
and contrasts different approaches for attributing the burden
reduction to vaccination conducted in those periods. The
estimates account for the long-term impact of vaccination
and the amount of transmission when vaccinees reach
adulthood.
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Results
Deaths and DALYs averted
Table 1 summarises the estimated number of deaths and DALYs
averted by each vaccination scenario, using different statistics for
calculating the number of deaths among cases whose mothers
would have been affected by vaccination in given periods.
Supplementary Figures S.1 and S.2 show the annual and cumula-
tive numbers of cases.
Using the base-case statistic, approximately 15, 75,000,
131,000, 41,000, 40,000 deaths were prevented with best-estimate
SIA coverage alone compared to that without additional support,
during 2001–10, 2001–20, 2001–30, 2011–15 and 2016–20 respec-
tively (Table 1). These were similar to those calculated using
statistics A and B, except for 2011–15 and 2016–20, for which
they differed by approximately 50% and 25% respectively. Using
statistic C led to increased predicted numbers of deaths because of
SIAs conducted during 2001–20 and 2016–20. Compared to zero
coverage, the deaths prevented by best-estimate SIA coverage
alone ranged between 29,000 and 850,000 for 2001–10 and
2001–30 respectively, and the estimates obtained using different
statistics generally differed by up to 20%.
Introducing routine vaccination without additional support
during 2001–30 was predicted to prevent 9,000 additional deaths
compared to SIAs alone conducted at best-estimate coverage,
increasing to 60,000 if routine vaccination was conducted with
best-estimate coverage. These estimates varied by vaccination
period, decreasing to approximately 1000 and 4000 deaths
respectively prevented when considering the period 2011–15,
but were generally insensitive to the statistic used.
For each scenario and period, patterns in the number of
DALYs prevented were similar to those for the number of deaths
prevented. For the base-case statistic, best-estimate SIAs alone
during 2001–30 were predicted to avert 12.5 million DALYs,
compared to those without additional support, increasing to
80 million DALYs averted when comparing best-estimate SIAs
against zero vaccination. For the same period, just under 1million
and 5 million DALYs were predicted to be averted through best-
estimate coverage for both SIAs and routine vaccination, com-
pared to best-estimate SIAs with routine vaccination without
additional support or zero levels respectively. Considering
2011–15 and 2016–20, SIA vaccination alone at best-estimate
coverage was predicted to prevent 4 million DALYs, compared
to SIA vaccination alone conducted at the coverage expected
without additional support.
Sensitivity analyses
Comparing SIAs alone against no vaccination for 2001–30,
the number of deaths prevented was relatively insensitive to
the assumed variation in vaccine efficacy and coverage
(Figure 1). The 95% range from varying the CRS risk follow-
ing maternal infection was 600,000–1.2 million deaths pre-
vented, increasing to 300,000–1.4 million deaths prevented
when varying either the CRS mortality rate or pre-vaccina-
tion force of infection. When varying all parameters simul-
taneously, the 95% range became 182,000–1.8 million deaths
prevented. Low and high fertility assumptions led to 20%
lower and higher average numbers of deaths prevented
respectively than those estimated for base-case parameter
values (Figure 1). The estimated number and 95% range of
deaths prevented resulting from basing the force of infection
on GBD grouping for countries lacking seroprevalence data
were similar to the base-case estimates.
When comparing best-estimate SIAs alone against zero vacci-
nation, the “reduced outside, best-estimate inside” approach led to
20–100% higher estimated numbers of deaths prevented, than for
the “best-estimate outside, reduced inside” approach for all peri-
ods except 2001–30 (Figure 2). It led to similar values for the other
vaccination scenario comparisons, except when comparing best-
estimate SIA and routine vaccination against best-estimate SIA
coverage with no routine coverage, when increased numbers of
deaths were predicted for several vaccination periods. For these,
increasing the coverage to best-estimate levels from zero or that
without additional support just for the vaccination period
Table 1. Estimates of the average number of CRS deaths and DALYS prevented through SIAs, with or without routine RCV vaccination carried out during 2001–10,
2001–20, 2001–30, 2011–15 and 2016–20 using different statistics for the number of cases among mothers affected by vaccination during a given period. See the
main text for a description of the statistics.
Deaths averted DALYs averted
Comparison Statistic 2001–10 2001–20 2001–30 2011–15 2016–20 2001–10 2001–20 2001–30 2011–15 2016–20
1. Best-estimate SIA alone vs
SIA without additional
support alone
Base-case 15 74,728 130,701 40,772 39,523 1362 7,139,512 12,509,331 3,851,097 3,798,699
A. 19 70,721 116,217 33,491 40,098 1733 6,725,936 11,087,188 3,161,694 3,837,194
B. 94 63,490 189,638 87,951 55,946 8669 5,816,900 18,261,846 8,387,707 5,257,221
C 26 −45,299 108,614 6554 −27,674 2427 −4,285,580 10,626,905 467,943 −2,595,230
2. Best-estimate SIA alone vs
no vaccination
Base-case 29,223 430,497 851,435 53,655 328,790 2,584,411 40,043,759 79,877,605 5,040,269 30,653,439
A. 26,920 375,495 805,343 45,893 273,475 2,382,642 34,891,178 75,501,986 4,306,514 25,502,913
B. 22,381 436,325 779,153 94,624 322,712 1,987,139 40,262,952 72,874,068 9,001,766 29,761,100
C 22,527 351,463 649,738 60,410 256,315 2,000,410 32,358,531 60,782,296 5,455,182 23,645,429
3. Best-estimate routine and
SIA vs best estimate SIA
and routine vaccination
without additional support
Base-case 0 8837 8724 1167 9358 0 825,997 814,591 108,333 873,833
A. 0 8905 8994 1136 9383 0 832,654 840,880 105,423 876,527
B. 0 8809 8704 1167 9330 0 823,264 812,602 108,333 871,100
C 0 8806 8704 1167 9327 0 823,057 812,602 108,333 870,893
4. Best-estimate routine
vaccination and SIA vs
best-estimate SIA and no
routine vaccination
Base-case 3984 18,498 57,912 4107 11,946 359,440 1,705,313 4,957,446 367,880 1,107,205
A. 3813 18,236 52,741 3761 11,782 344,760 1,682,343 4,542,776 339,174 1,093,868
B. 4488 19,373 58,198 4700 12,861 405,581 1,785,642 4,982,807 421,517 1,187,713
C 4570 19,095 58,198 4686 12,507 413,122 1,759,933 4,982,816 420,312 1,155,045
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considered led to an increased predicted incidence and a negative
predicted impact (Figures S.3 and S.4, Supplement).
Discussion
We estimate that approximately 131,000 CRS deaths and 12.5mil-
lion DALYs may be prevented by increasing the coverage in SIAs
from those expected without additional support to best-estimate
levels in 92 countries during 2001–30, with 60,000 additional
deaths and 5 million DALYs prevented by introducing routine
vaccination. The morbidity and mortality prevented depended on
the period considered, with approximately 40,000 deaths and
4 million DALYs prevented through SIAs conducted during
2011–15 and 2016–20. Approximately 850,000 CRS deaths and
80 million DALYs are predicted to be prevented through SIAs at
best-estimate coverage, compared to zero vaccination.
Our analyses appear to be the first to estimate the reduction in
the burden of CRS that may be attributable to vaccines adminis-
tered in specific periods, also accounting for the complication that
the outcome prevented (CRS) occurs many years after the vaccine
is administered. As such, the reduction in the CRS burden that is
attributable to vaccination in a given period is influenced both by
the vaccination coverage among pregnant women during their
childhood and the population-level coverage thereafter. Whilst
our analyses focussed on rubella and CRS, analogous issues also
apply to other infections for which the outcome prevented occurs
many years after the vaccination is administered, such as hepatitis
and HPV, for which vaccination may prevent liver and cervical
cancers respectively. GAVI presently provides funding for eligible
countries to introduce vaccines for both infections and so also
measures its progress using the number of future deaths and
DALYs averted through vaccination conducted in given periods
for these infections.
We calculated the numbers of deaths among those born to
mothers affected by vaccination in given periods using four sta-
tistics. The base-case and statistic A used the average number of
deaths during given periods and statistics B and C used the total
number of deaths since the period starts until 44 or 49 years after it
finishes. The first two statistics have the advantage over the other
two of being less sensitive to predictions of outbreaks. For exam-
ple, statistic C predicted more deaths with best-estimate coverage
for two periods than with coverage at levels which might be seen
without additional support. This followed from predictions of
many cases occurring towards the end of the period used in
calculating the number of deaths, which outweighed the reduced
number of deaths which had been predicted until then if the
coverage was at levels expected without additional support during
the periods of interest (Figure S.1, Supplement).
We used two approaches for estimating the impact of
vaccination conducted during a period. The impact estimated
from the “best-estimate outside, reduced inside” approach is
interpretable as the contribution of vaccination conducted
during that period to the impact of vaccination conducted
from 2001 onwards. The “reduced outside, best-estimate
inside” approach provides the literal definition of the impact
of vaccination conducted during given periods, but has the
disadvantage of comparing one scenario against one that
could lead to increases in CRS incidence, such as best-esti-
mate coverage within 2011–15 which decreases thereafter.
This scenario reduces transmission during the vaccination
period, leading to increases in the average age at infection
for unvaccinated people, which, combined with increased
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Figure 1. Sensitivity of estimates of the average number of CRS deaths prevented through best-estimate SIAs carried out during 2001–30, compared against no
vaccination. The light grey bars show the values obtained for the base-case (median variant) fertility, with the thin bars reflecting the 95% range obtained after
varying the parameter indicated on the x-axis individually. The thin bars on the dark grey or white bars show the 95% range obtained after varying all the parameters
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transmission predicted once vaccination stops, leads to an
increased CRS incidence and an apparently negative predicted
impact of vaccination conducted during 2011–15.
Our analyses suggest that, considering the period 2001-10
very few deaths from CRS were prevented because of SIAs
conducted at best-estimate coverage, compared to that with
coverage which would have occurred without additional sup-
port. The reason for this low number is that the period 2001–10
predates the year when increased funding became available for
countries to introduce Measles-Rubella vaccination.
Consequently, for that period, the best-estimate coverage for
SIAs is similar to the vaccination coverage which would have
been seen without additional support.
Our analyses include several limitations. First, our estimates
depend on the assumed pre-vaccination epidemiology of rubella,
with datasets available for 30 of the 92 countries considered. These
data, in turn, have several limitations,1 for example, being con-
venience samples from antenatal clinics, which may not represent
the general population, and from cross-sectional surveys. For
countries lacking serological data, data according to WHO or
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GBD regionwere used instead.We also note that several populous
countries, including Afghanistan, Nigeria and Pakistan influence
our estimated total number of CRS deaths prevented.
Second, for simplicity, we only included one dose of routine
vaccination in our analyses, whereas two doses, including measles
vaccine, are often provided. As we assumed that both the routine
coverage was high and vaccine-derived immunity is lifelong,
excluding the second dose would not have affected conclusions
greatly: including it would just give the 5% of vaccinees without
immunity after the first dose an opportunity to become immune.
Third, we may have overestimated the number of DALYS
averted, as a country’s World Bank income group in 2017 deter-
mined their assigned DALY, with low-income groups assigned
higher DALYS than high-income groups (29.2 vs 22.9 respec-
tively). Such differences result fromassumptions that high-income
countries may provide better treatment for several CRS-related
disabilities (e.g. cataract and deafness) than low-income countries.
A final limitation is that for simplicity, we did not account
for the possibility that CRS cases may die many years after
birth. The estimated CRS-related mortality rate to date has
been based on short follow-up periods after birth (up to a
year) and so may be an underestimate.
In conclusion, our analyses suggest that ongoing immuni-
zation activities could prevent substantial numbers of CRS-
related deaths and DALYs. With increasing interest in measles
elimination and introducing RCV, the number of deaths that
are ultimately prevented through RCV may increase further.
Further surveillance and serological studies are needed to
improve the reliability of the estimated mortality prevented
and monitor changes after introducing vaccination.
Materials and methods
Demographic data
We considered 92 low and middle-income countries
(Table S.1, Supplement) which the Decade of Vaccines
(DoV10 collaboration considered to be most likely to require
global support to achieve the Global Vaccine Action Plan’s
objectives.11 The following UN demographic country-specific
data were used:12 a) Annual medium variant, sex-specific
population size during 2001–2081, stratified by single-year
age-groups; b) Age and sex-specific survival rates for
2010–15; c) Medium, high and low variants of the age-specific
fertility rates in 5-year age groups projected until 2080; d)
Crude birth rates for 2010–15.
Description of the transmission model
General structure and demography
We used an age and sex-structured, deterministic, compart-
mental model of the transmission dynamics of rubella, follow-
ing previous work.1,13 The population is stratified into those
with maternal immunity (lasting 6 months), susceptible, pre-
infectious (infected but not yet infectious), infectious and
immune, using annual age bands and a “Realistic Age
Structure.14 Country-specific birth and age-specific death
rates were fixed at 2010–15 levels and calculated from UN
population survival data for 2010–15 respectively.12 The sup-
plement to13 provides the model’s differential equations.
The force of infection and pre-vaccination epidemiology of
rubella
The force of infection (rate at which susceptibles are infected)
changes over time and is calculated using the number of
infectious individuals and the effective contact rate (rate at
which infectious and susceptible individuals come into effec-
tive contact). Contact is described using the following matrix
of “Who Acquires Infection From Whom”:
β1 0:7β2
0:7β2 β2
 
The effective contact rate differs between < 13 and ≥ 13 year
olds, with its relative size based on contact survey data.15 β1 and
β2 are calculated from the average force of infection in < 13 and
≥ 13 year olds, estimated from age-stratified rubella seropreva-
lence data, which had been collected before RCV was
introduced.1 Seroprevalence data were available for 25 countries
as described in,1 with additional data (Supplement – sections A
and B) for Cambodia,16 Democratic Republic of the Congo,17
Burkina Faso,18 Kenya19 and Tanzania20 identified through a
systematic review, and unpublished data from Indonesia (S Reef,
personal communication, March 2015). For countries lacking
seroprevalence data, we used data from countries in the same
WHO region (Supplement – section B and1). Confidence inter-
vals (CI) on the force of infection were calculated using 1000
bootstrap-derived-seroprevalence datasets 1 and Supplement
-section A).
Numbers of CRS cases, deaths and dalys
Country-specific numbers of CRS cases in year y during
2001–2080 were calculated by summing the number of CRS
cases born each day to women aged 15–44 years (Supplement –
section C). As assumed elsewhere,1,9,13 infection during the first
16 weeks of pregnancy carries a 65% risk of the newborn having
CRS (Table 2). The number of CRS deaths in year ywas calculated
by multiplying the number of CRS cases born in year y by the
assumed case fatality rate (30% – see Table 2). The number of
DALYs for cases in year y was calculated by multiplying the
number of CRS cases in year y by the corresponding DALY
(from29), which was based on the country-specific World Bank
Income group for 2017.30 Both the DALYs and the assigned
World Bank income group remained fixed over time.
Deaths and dalys averted
Vaccination coverage definitions and scenarios
In these analyses, we define the “best-estimate coverage” as the
highest realistic vaccination coverage whichmight be attained in a
country and the “Coverage without additional support” as the
coverage that might be seen if a country receives no further
external support. In practice, a country may attain best-estimate
coverage if it receives additional external support. By definition,
the best estimate coverage equals the coverage seen without addi-
tional support in countries which introduced RCVwithout having
received additional external support.
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We calculated the average number of CRS deaths and
DALYs prevented by vaccination conducted during
2001–2010, 2001–2020, 2001–2030, 2011–2015, 2016–2030
for the following:
(1) Special Immunization Activities (SIAs) at best-estimate
coverage compared to SIAs conducted without addi-
tional support, both without routine immunization;
(2) SIAs at best-estimate coverage, without routine vac-
cination compared to no vaccination;
(3) Both routine and SIA vaccination at best-estimate
coverage, compared to SIAs at best-estimate coverage
without routine vaccination;
(4) Both routine and SIA vaccination at best-estimate cover-
age compared to routine vaccination without additional
support but with SIAs at best-estimate coverage.
The projected vaccination coverage was based on Gavi’s
Strategic Demand Forecast, version 124 and the historical
coverage during SIAs and routine vaccination came from
WHO and WUENIC estimates for measles-containing vaccine
(MCV1) respectively.31,32 To facilitate between-scenario com-
parisons, 2000 was the earliest year for introducing
vaccination.
For simplicity, routine vaccination is provided as a single
dose in the model. Comparisons 1 and 2 demonstrate the
incremental impact of best-estimate coverage in campaigns
(relative to that without additional support or no vaccination),
and include hypothetical scenarios, as they consider cam-
paigns in the absence of routine immunization. In reality,
the latter would be necessary for introducing rubella vaccina-
tion. Comparisons 3 and 4 show the incremental effect of
adding routine vaccination to vaccination in mass campaigns.
Attributing deaths and DALYs prevented to vaccination
conducted in specific periods
In the base-case for each comparison we used a “best-
estimate outside, reduced inside” approach (Figure 3A,B)
to calculate the numbers of deaths and DALYs averted by
vaccination administered during the period ys  ye, where
ys and ye are the first and last years of the period.
Considering deaths for comparisons 1 and 2, this number
was calculated as the difference in the number of CRS
deaths associated with the period (see definitions below)
with SIAs at best-estimate coverage and the corresponding
number of deaths for the same scenario but with SIA
coverage at the alternative (reduced) level within the period
(ys  ye). The calculation for comparisons 3 and 4 and
DALYs is analogous.
We define the number of CRS deaths that are associated with
a period ys  ye, (denoted GCysye) as the number of CRS deaths
among those CRS cases whosemothers would have been affected
by vaccination conducted during ys  ye. For a given coverage, c,
during ys  ye, this was calculated as the average of the cumula-
tive number of CRS deaths from the start of the period until
14–49 years after the period ends, as follows:
Gcysye ¼
X49
i¼14
Dys; ye þ i
36
where Dys; ye þ i is the total number of CRS deaths from years
ys to ye þ i. The summation covers the reproductive lifespan
of people vaccinated during ys  ye. The number of deaths
and DALYs averted were summed for all countries.
Sensitivity analyses
We also estimated the numbers of deaths (and similarly,
DALYS) prevented by vaccination conducted in the periods
of interest using alternative statistics for the number of deaths
among cases whose mothers would have been affected by
vaccination administered during ys  ye:
A. The average of the cumulative number of CRS deaths
since the period starts (ys) until 49 years from its endP49
i¼0
Dys;yeþi
50
 
.
B. The total number of deaths since the period starts until
44 years from its end Dys;yeþ44
 
.
C. The total number of deaths since the period starts until
49 years from its end Dys;yeþ49
 
.
Table 2. Summary of the basecase and ranges of the parameters used in the model.
Base-case value
Values used in sensitivity
analyses Basis
Pre-vaccination force of
infection (used to
calculate contact
parameters)
Based on pre-vaccination
seroprevalence data from the country
(if available) or from the same WHO
region otherwise.
1000 bootstrap-derived values See 1.
Vaccine efficacy 95% 85% to 99%, sampled from the
truncated Beta distribution with
parameters α = 33 and ß = 2.
Plausible values
CRS-related mortality rate 30% Sampled from the uniform
distribution in the range
10–50%.
3 studies in Vietnam, Greece and Panama in which
the 95% confidence intervals were 20–51%, 12–50%
and 15–40% respectively 21–23.
Vaccination coverage From historical projections24 10% higher or lower each year
than historical projections.
Plausible
Risk of a child being born with
CRS if the mother is infected
during the first 16 weeks of
pregnancy
65% Sampled from the Gamma
distribution with shape and
scale parameters 37 and 56
respectively.
Lead to a median and 95% range of 65% and
47–88% respectively consistent with those from
several studies25-27 which, as found in a recent
review28 were likely to have been more reliable than
those in other studies.
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We estimated the sensitivity of the base-case impact statis-
tic to the input parameters by calculating the 95% range of its
values after sampling each parameter in Table 2 1000 times
individually and simultaneously. Point estimates and the 95%
range of the outcomes were also calculated using:
(1) UN population projections of high and low variants
of the fertility rates.
(2) Bootstrap-derived values for the force of infection com-
piled from seroprevalence data from countries in the
same Global Burden of Disease (GBD) region instead of
the same WHO regio33 (Table S.5, Supplement) for
countries which had no seroprevalence data.
Finally, we explored the effect of the “reduced outside,
best-estimate within” approach (Figure 3C,D) on the esti-
mated number of deaths averted, i.e. using vaccination at
zero/reduced coverage outside the period considered and
best-estimate levels within it, using the base-case statistic
to calculate the number of deaths among cases whose
mothers were affected by vaccination during the period.
Abbreviations
CRS Congenital Rubella Syndrome
DALY Disability Adjusted Life Years
MR Measles-Rubella
RCV rubella-containing vaccine
ys ye
Zero coverage
throughout
Zero outside, best-
estimate within
ys ye
Best-estimate outside,
zero within
Best-estimate
throughout
yeys
Best-estimate outside,
without additional
support within
Best-estimate
throughout
Without additional
support throughout
Without additional
support outside, best-
estimate within
egarevoc noitanicca
V
Time
A. B.
C. D.
ys ye
Figure 3. Schematic of the coverage used to calculate the number of deaths and DALYs averted from vaccination administered in a given period of interest (ys-ye),
indicated by the double-headed arrow. Figures A and B show the two coverage assumptions used to estimate the impact of vaccination during a period of interest
using the “best-estimate outside, reduced inside” approach. Figures C and D show the two coverage assumptions used to estimate the impact of vaccination using
the “reduced outside, best-estimate inside” approach. For each scenario, the difference between the numbers of deaths associated with the period of interest with
coverage set at that for the red line and that for the blue line gives the number of deaths averted. The numbers of deaths averted through best-estimate SIA
vaccination conducted during 2011–15, for example, is calculated as the difference between the number of deaths among those born to mothers affected by
vaccination during this period for the scenarios of no vaccination at all and zero coverage outside 2011–15 and best-estimate coverage during 2011–15.
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